Pipeline

Have BMS and Gilead found the 'killer app' for hep. C?

April 19, 2012

Scientists are getting closer to finding the killer app in treating hepatitis C, but it may be too soon to pick a winner.
 

Shire exits Fabry's market, citing costs as FDA weighs more research

March 15, 2012

Shire has pulled its drug, Replagal, from FDA review. The company was set to go before the agency next month, but preliminary talks indicated the FDA was going to require more testing.
 

An FDA denial, but not the last word on Merck combo lipid drug

March 06, 2012

An experimental lipid-lowering combo drug developed by Merck hit a snag, but its real test is yet to come, says one analyst.
 

Company news: Biogen-Idec, Bristol-Myers Squibb and Pfizer

February 29, 2012

Biogen-Idec is submitting its multiple sclerosis drug BG-12 for formal FDA scrutiny.
 

Sanofi contest gooses diabetes tech innovation

February 23, 2012

Sanofi is re-upping its social media-driven Data Design Diabetes Innovation Challenge contest, which last year kicked up a wealth of innovative ideas and buzz for the price of $200,000 in prize money and a few salaries.
 

Setback, not disaster, for Gilead hep. C regimen, analysts say

February 21, 2012

In the race to develop an all-oral hepatitis C therapy, Gilead Sciences just saw its lead shrink.
 

Company news: Gilead, Pfizer and Wolters Kluwer

December 29, 2011

Two potential blockbusters in the pharma pipeline took another step toward reaching market, as US regulatory authorities assigned PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib.
 

Since Vioxx scare, tough times for industry R&D, study finds

December 01, 2011

A review of 450 New Molecular Entities spanning a decade and a half found two distinct eras of drug R&D - one of abundance and one of scarcity, hinging on the September, 2004 withdrawal of Merck's Vioxx.
 

New indication may give Xarelto a sales boost

October 04, 2011

Will Xarelto become the first Factor Xa inhibitor with an indication for use in patients who have had a heart attack or similar symptoms?
 

European meeting may clear the air on Eliquis

August 23, 2011

Experts are looking forward to an international cardiology meeting this weekend to help answer a key question: Will Eliquis become the leading substitute for warfarin?
 

Renewed focus on Alzheimer's could help new drugs to market

December 16, 2010

The House's passage of the National Alzheimer's Project Act yesterday - should it be signed into law by President Obama - could help expedite the approval process for new drugs targeting the disease, sources say.
 

Merck Serono calls for short film scripts in global MS effort

May 26, 2010

Merck Serono announced the launch of a global MS awareness campaign calling for "script concepts" on the topic of multiple sclerosis. The winning script will be developed into a short film and distributed later in 2010. The contest is not open to US residents.
 

Pfizer aborts investigational compounds, reprioritizes

February 24, 2009

Pfizer terminated phase 3 development on two investigational compounds today after halting trials on axitinib, a phase 3 pancreatic cancer treatment, in January.
 

MPR rolls out revamped website

January 20, 2009

Monthly Prescribing Reference (MPR) has relaunched its website with a number of enhancements to functionality and design, as well as a new, easier-to-remember URL, www.eMPR.com.
 

Merck makes a play for generic biologics market

December 11, 2008

Merck is betting on Democratic plans to speed development of generic biologics, making a play for the market with a new unit tasked with designing the products and promising, in the words of president and CEO Dick Clark, a "new Merck built for the new era that our industry has entered."
 

Pfizer brags of pipeline, refocuses R&D

October 02, 2008

Pfizer announced that the number of compounds it has in Phase 3 development has grown from 16 to 25 over the past six months, including eight cancer treatments.
 

Thomson Reuters names five most promising Q1 drugs

August 18, 2008

A Thomson Reuters study forecasts five of the "most promising drugs launched or receiving approval" during the first quarter of 2008.
 

IMS projects seven potential blockbusters

May 22, 2008

Seven potential blockbusters could emerge in 2008, according to IMS Health.
 

Product news

March 18, 2008

Hawthorn Pharmaceuticals announced the FDA approval of the company's Granisol (granisetron HCl) oral solution. Granisol is an oral solution for the prevention of nausea and vomiting associated with cancer therapy.
 

Alkermes: Lilly to end inhaled insulin deal

March 07, 2008

Biotech firm Alkermes said today it expects Eli Lilly to soon back out of its inhaled insulin development deal between the companies.
 

Ambling toward patent cliff, flinty Pfizer boasts of pipeline

March 06, 2008

Pfizer delivered a low-key analyst day, offering no surprises as it advances toward a "cliff" of patent expirations on major products.
 

FDA delays Requip XL approval

February 06, 2008

The FDA has delayed approval of GlaxoSmithKline and SkyePharma's reformulated Requip XL (ropinirole) as a treatment for Parkinson's disease.
 

FDA approves fewest novel drugs in 24 years: reports

January 08, 2008

The FDA approved 19 novel drugs last year, the lowest number since 1983, according to published reports.
 

Takeda submits NDA for Actos replacement as DPP-IV pipeline heats up

January 07, 2008

Takeda Pharmaceutical has submitted a new DPP-IV diabetes drug candidate -- Alogliptin -- in hopes the drug will replace its major earner Actos which loses patent protection in 2011.
 

Sepracor in licensing pact for anti-epileptic compound

January 03, 2008

Sepracor has entered a licensing deal with Bial for the development and commercialization of Bial's anti-epileptic compound BIA 2-093 in the US and Canada.
 

Company news

January 03, 2008

Merck and Addex Pharmaceuticals entered a deal to develop a drug candidate for schizophrenia, under which Merck will pay Addex up to $702 million in cash plus royalties.
 

Wyeth sees generic threats, another delay on Viviant

December 26, 2007

Competitors have stepped up efforts to market generic versions of some of Wyeth's biggest drugs, threatening to sap hundreds of millions of dollars in sales.
 

FDA seeks more info on Cervarix

December 17, 2007

GlaxoSmithKline said approval of Cervarix will be delayed in the US after FDA regulators requested more information on the vaccine in a "complete response letter" to the drugmaker.
 

Novartis planning four new cancer drugs: Oncology president says

December 05, 2007

David Epstein, president of Novartis Oncology, said he hopes the drug maker will be able to start selling four new cancer treatments by the year 2011.
 

MM&M launches New Drug Dossier

November 30, 2007

MM&M's New Drug Dossier is designed to give pharmaceutical marketers authoritative promotional and clinical insights on the latest new molecular entities in one online resource.
 

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
 

MM&M Awards 2011 HIghlights

The Best MM&M Awards Ever!

MAHF Ceremony 2012

Photos from the Medical Advertising Hall of Fame Awards ceremony
 
Popular Topics
Acquisition Adherence App Celebrity Clinical Trial Co-Marketing Diabetes Diagnostics Digital Direct To Consumer (DTC) Disease Awareness Downsize Education & Awareness FDA Government Guidance Health Plans HMOs Hospitals Insurers Law Marketing Research Medical Journal Mobile Sales Force